Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231.
Alzheimer’s disease
Analytical validation
Blood biomarkers
Clinical validation
P-tau181
P-tau217
P-tau231
Phosphorylated tau proteins
Simoa
Ultra-sensitive immunoassays
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
04 12 2021
04 12 2021
Historique:
received:
03
08
2021
accepted:
16
11
2021
entrez:
5
12
2021
pubmed:
6
12
2021
medline:
11
3
2022
Statut:
epublish
Résumé
Studies using different assays and technologies showed highly promising diagnostic value of plasma phosphorylated (P-)tau levels for Alzheimer's disease (AD). We aimed to compare six P-tau Simoa assays, including three P-tau181 (Eli Lilly, ADx, Quanterix), one P-tau217 (Eli Lilly), and two P-tau231 (ADx, Gothenburg). We studied the analytical (sensitivity, precision, parallelism, dilution linearity, and recovery) and clinical (40 AD dementia patients, age 66±8years, 50%F; 40 age- and sex-matched controls) performance of the assays. All assays showed robust analytical performance, and particularly P-tau217 Eli Lilly; P-tau231 Gothenburg and all P-tau181 assays showed robust clinical performance to differentiate AD from controls, with AUCs 0.936-0.995 (P-tau231 ADx: AUC = 0.719). Results obtained with all P-tau181 assays, P-tau217 Eli Lilly assay, and P-tau231 Gothenburg assay strongly correlated (Spearman's rho > 0.86), while correlations with P-tau231 ADx results were moderate (rho < 0.65). P-tau isoforms can be measured robustly by several novel high-sensitive Simoa assays.
Identifiants
pubmed: 34863295
doi: 10.1186/s13195-021-00939-9
pii: 10.1186/s13195-021-00939-9
pmc: PMC8645090
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Protein Isoforms
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
198Subventions
Organisme : NIA NIH HHS
ID : R01 AG068398
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Acta Neuropathol. 2021 May;141(5):709-724
pubmed: 33585983
Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12132
pubmed: 33614897
J Alzheimers Dis. 2018;62(3):1091-1111
pubmed: 29562540
Acta Neuropathol. 2020 Sep;140(3):267-278
pubmed: 32720099
Nat Commun. 2020 Apr 3;11(1):1683
pubmed: 32246036
Lancet. 2021 Apr 24;397(10284):1577-1590
pubmed: 33667416
Nat Med. 2020 Mar;26(3):387-397
pubmed: 32123386
Mov Disord. 2021 Mar;36(3):767-771
pubmed: 33285015
Alzheimers Dement. 2021 Aug;17(8):1353-1364
pubmed: 33580742
Nat Med. 2020 Mar;26(3):379-386
pubmed: 32123385
J Neurol Neurosurg Psychiatry. 2020 Sep;91(9):960-967
pubmed: 32611664
Alzheimers Res Ther. 2020 Mar 17;12(1):26
pubmed: 32183883
J Alzheimers Dis. 2014;41(1):313-27
pubmed: 24614907
Lancet. 2016 Jul 30;388(10043):505-17
pubmed: 26921134
Brain. 2021 Feb 12;144(1):325-339
pubmed: 33257949
Mol Psychiatry. 2021 Feb;26(2):429-442
pubmed: 33106600
JAMA Neurol. 2021 Feb 1;78(2):149-156
pubmed: 33165506
Front Neurol. 2015 Aug 19;6:179
pubmed: 26347708
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32725127
JAMA. 2020 Aug 25;324(8):772-781
pubmed: 32722745
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
JAMA Neurol. 2021 Sep 1;78(9):1108-1117
pubmed: 34309632
JAMA Neurol. 2019 Jul 1;76(7):791-799
pubmed: 31009028
Lancet Neurol. 2020 May;19(5):422-433
pubmed: 32333900
Brain. 2021 Mar 3;144(2):434-449
pubmed: 33479777
Cell. 2020 Dec 10;183(6):1699-1713.e13
pubmed: 33188775
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132